Restless legs syndrome management has changed more in the past five years than in the previous twenty, and the changes are mostly for the better. The shift away from dopamine agonists as first-line therapy, the renewed focus on iron status, and the broader use of alpha-2-delta ligands have substantially improved outcomes for the patients who actually get to a clinician informed enough to follow current evidence. Many don’t.

This is a quick clinical update on where RLS management sits in May 2026, with attention to the practical decisions that come up in outpatient sleep medicine.

The dopamine agonist retreat

Augmentation — the paradoxical worsening of RLS symptoms with prolonged dopamine agonist use — was always the dirty secret of pramipexole and ropinirole therapy. We’ve known about it for two decades. The 2024 IRLSSG consensus paper on augmentation moved the needle by being unambiguous: dopamine agonists should not be first-line for chronic RLS. The American Academy of Sleep Medicine and the European Sleep Research Society aligned around this position over 2024–2025.

In Australian practice, the implications are slow to filter through. A meaningful proportion of patients I see in clinic have been on long-term pramipexole prescribed by primary care or general neurology, often at doses well above 0.5 mg per day, with classic augmentation features that have been misinterpreted as disease progression. Tapering off these patients is genuinely hard. The withdrawal phase can be brutal, and patients need clear coaching that the worsening they’ll experience is temporary.

I’ve found a slow taper over 8–12 weeks, with bridging gabapentinoid therapy and aggressive iron supplementation if indicated, gives the best outcomes. Patient counselling matters more than the pharmacology — explaining that things will get worse before they get better, and being available for support during the transition.

Iron, again, and properly

The iron-RLS relationship is finally being managed with appropriate seriousness in clinical guidelines. The threshold for considering supplementation has moved up — current consensus suggests treating ferritin under 100 µg/L (not the older 50 µg/L threshold) in patients with troublesome RLS, with transferrin saturation below 20% as an additional consideration.

Oral iron remains first-line for compliance and cost reasons, but the alternate-day dosing literature has improved adherence and absorption outcomes. For patients who don’t respond to oral therapy or have significant gut intolerance, IV iron — typically ferric carboxymaltose — has moved into routine RLS management. The Sleep Foundation’s 2025 RLS treatment guidance includes specific protocols for IV iron administration in this indication.

The MBS rebate situation for IV iron in RLS is awkward — the indication isn’t formally approved on PBS, and many infusion centres won’t administer without a haematological indication. I’ve had reasonable success working with patients’ GPs to coordinate infusion under combined-rationale frameworks, but it’s frustrating that the system makes a well-evidenced intervention this hard to access.

Gabapentinoids as workhorses

Gabapentin enacarbil is the only gabapentinoid with a specific RLS approval in the US, but in Australian practice we mostly use generic gabapentin or pregabalin off-label, and the evidence supports both. Pregabalin at 150–300 mg nocte is my usual go-to for moderate-severe RLS without significant comorbidity. Gabapentin at 600–1800 mg nocte works but the dose-response curve is less predictable.

The opioid use disorder concerns about gabapentinoids in pain medicine are real but largely don’t apply to the RLS population at typical effective doses. Sedation and weight gain are the practical limitations. Cognitive impairment in elderly patients is worth specifically watching for, and dose adjustment for renal function matters.

Low-dose opioids — the conversation we need to have

Low-dose oxycodone or methadone for severe refractory RLS is well-supported by evidence including the Mass General-Harvard registry data published in Sleep last year. Australian regulatory and prescribing culture has not embraced this in the way that, say, the US sleep medicine community has. There are good reasons for caution, but there’s also a small population of patients with genuinely severe disease who don’t respond to gabapentinoids, can’t tolerate dopamine agonists, and would benefit from low-dose opioid management with appropriate oversight.

The clinical conversation in Australia needs to move forward on this. The TGA framework allows it. The PBS rebate situation is unhelpful but workable. The professional reluctance is partly cultural. The Australasian Sleep Association has a working group looking at this.

Comorbidity matters

RLS sits at intersections with several other conditions worth flagging. Iron-deficient pregnancy is a common precipitant. End-stage renal disease patients have very high RLS prevalence and respond differently to standard treatments. Patients on SSRIs, particularly mirtazapine, can have RLS exacerbated or precipitated. The medication review is often where the management plan starts.

Periodic limb movement disorder is a related but distinct condition, and the treatment overlap is partial. PLMD without RLS symptoms is a treatment dilemma — many of these patients don’t actually need pharmacological intervention if daytime function is preserved.

What the workforce situation means in practice

The reality of RLS care in Australia is that most patients are managed by primary care, often without ferritin testing, often with default dopamine agonist prescriptions, and rarely with structured follow-up. That’s not a criticism of GPs — it’s a system issue with sleep medicine workforce that I’ve written about elsewhere. The Sleep Health Foundation’s GP education materials on RLS were updated in late 2025 and are genuinely good. Worth recommending to your referring colleagues.

The bottom line for 2026 practice: check ferritin, treat iron deficiency aggressively, use gabapentinoids early, avoid first-line dopamine agonists, and have the difficult conversations about low-dose opioids in refractory disease. The therapeutic toolkit is better than it’s been. Using it well is the bit that takes attention.